2020-12-02
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read the full press release: https://www.camurus.com/
2022-12-12
Through a private placement the family-owned investment company Sandberg Development will become a new owner of COT…
Read more2022-12-05
Fredrik Sjöholm is since 2016 is VP Sales at Precise Biometrics and has a long relevant background within internatio…
Read more2022-11-25
In 2018 Sandberg Development invested in the water technology company SWATAB. Sandberg Development now acquires the…
Read more2022-11-10
Camurus' Interim Report for the third quarter, which was published today, showed that this was Camurus' financially…
Read more2022-11-01
Sandberg Development aim to improve sustainable and commercial solutions and to create new ones for the future. To a…
Read more